These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21948166)

  • 1. Application of radiotherapy and chemotherapy protocols to pre-clinical tumor models.
    Burd R; Wachsberger P
    Curr Protoc Pharmacol; 2007 Sep; Chapter 14():Unit 14.7. PubMed ID: 21948166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental evaluation of functional imaging for radiotherapy.
    Zips D; Yaromina A; Schütze C; Wüllrich K; Krause M; Krause M; Hessel F; Eicheler W; Dörfler A; Brüchner K; Menegakis A; Zhou X; Bergmann R; van den Hoff J; Beuthien-Baumann B; Baumann M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():41-2. PubMed ID: 18167009
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
    Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
    Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
    Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
    Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the orthotopic model to validate antivascular therapies for cancer.
    Loi M; Di Paolo D; Becherini P; Zorzoli A; Perri P; Carosio R; Cilli M; Ribatti D; Brignole C; Pagnan G; Ponzoni M; Pastorino F
    Int J Dev Biol; 2011; 55(4-5):547-55. PubMed ID: 21858775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of p53 status on tumor response to antiangiogenic therapy.
    Yu JL; Rak JW; Coomber BL; Hicklin DJ; Kerbel RS
    Science; 2002 Feb; 295(5559):1526-8. PubMed ID: 11859195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins.
    Dienst A; Grunow A; Unruh M; Rabausch B; Nör JE; Fries JW; Gottstein C
    J Natl Cancer Inst; 2005 May; 97(10):733-47. PubMed ID: 15900043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
    Wachsberger P; Burd R; Dicker AP
    Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay.
    Geng L; Osusky K; Konjeti S; Fu A; Hallahan D
    J Control Release; 2004 Oct; 99(3):369-81. PubMed ID: 15451595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors.
    Mason KA; Neal R; Hunter N; Ariga H; Ang K; Milas L
    Radiother Oncol; 2006 Aug; 80(2):192-8. PubMed ID: 16905212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new concept of the formation of hypoxic cells in tumors and its possible implications for radiotherapy and chemotherapy.
    Ng CE
    Med J Malaysia; 1981 Mar; 36(1):24-8. PubMed ID: 7321933
    [No Abstract]   [Full Text] [Related]  

  • 17. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
    Dings RP; Williams BW; Song CW; Griffioen AW; Mayo KH; Griffin RJ
    Int J Cancer; 2005 Jun; 115(2):312-9. PubMed ID: 15688384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM; Paoni SF
    Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
    Slagel DE; Feola J; Houchens DP; Ovejera AA
    Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.